anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
AIMS: Per-oral endoscopic myotomy (POEM) is a recognised treatment for achalasia, with the accepted approach involving admission for imaging and dietary progression. However, recent publications suggest same-day discharge (SDD) may be possible, which could be time and cost-saving. We sought to investigate the safety of SDD following POEM.
METHODS: Fifty consecutive POEMs at two referral centres in New Zealand were performed between 2020-2023. All patients were planned for early dietary introduction and were eligible for SDD if symptoms were managed. Analgesia was available in recovery and supplied at discharge. Imaging and endoscopy were performed only if there were clinical concerns. Rates of discharge clearance, discharge, complications and re-admission were analysed.
RESULTS: All 50 POEMs were technically successful. A total of 41/50 (82%) received clearance for SDD. Additionally, 35/50 (70%) achieved discharge and 6/50 (12%) were observed overnight for social reasons, including lack of transport to the referring domicile. Of the patients not cleared for SDD, 7/9 (78%) were discharged within 24 hours, and the others after 48 and 72 hours. Procedural complications were recorded in three patients (6%), with one requiring endoscopic assessment and clipping. There were two re-admissions (4%), both lt;24-hour hospital stays, and managed medically.
CONCLUSIONS: The majority of patients achieved same-day discharge clearance (82%) and 96% required less than 24 hours hospital stay. Complication and re-admission rates were low overall. We have demonstrated that POEM can be an SDD procedure facilitated by early dietary introduction and liberal analgesia, without the need for routine imaging or endoscopy.
The invention relates to the milk of a transgenic non-human mammal. The milk is characterized in that it contains heterologous components produced as the secondary gene products of a heterologous gene contained in the genome of the transgenic non-human mammal. The heterologous gene encodes a heterologous catalytic entity such as a human enzyme selected from the group consisting of glycosyltransferases, phosphorylases, hydroxylases, peptidases and sulfotransferases. Especially useful in the practice of the invention are human glycosyltransferases. The desired heterologous components include oligosaccahrides, glycoconjugates. Specifically exemplified, is the production of 2'-fucosyl-lactose in the milk of transgenic mice which contain and express a transgene encoding α-1,2-fucosyltransferase operatively linked to a mammary gland specific promoter. The oligosaccahrides and glycoconjugates may be isolated from the milk of the transgenic mammals and used in the preparation of pharmaceuticals, diagnostic kits, nutritional products and the like. The whole transgenic milk may also be used to formulate nutritional products that provide special advantages. The transgenic milk may also be used in the production of specialized enteral nutritional products.
PURPOSE: To produce a factor VIII analog, capable of manifesting normal procoagulant activities and efficiently expressible in a mammalian cell by deleting amino acids within a specific range. CONSTITUTION: This factor VIII analog is a compound deleted from amino acids 771 to 1,666 in a region corresponding to a domain B. The factor VIII analog is obtained by preparing a cDNA of the factor VIII in which the amino acids 771 to 1,666 are deleted from a plasmid pTG1080, containing the cDNA of the factor VIII and nucleotides-64 to 8230 cloned in an Sal1 site of a pUC8, integrating the resultant cDNA into a vaccinia viral genome, providing a recombinant virus VV. TG. FVIII1507, infecting a eukaryocyte (e.g. a BHK21 cell) with the recombinant virus, culturing the resultant eukaryocyte on a culture medium and separating the produced factor VIII analog.
A randomized, controlled trial with cross-over design in which the subjects (23 patients with an oncological disease, 13 healthy controls) receive warm water footbaths with added ginger (experimental) or mustard powder (experimental) or without additives (active comparator). The wash-out period between two consecutive footbath interventions is at least one day. Outcome measures are assessed right before (t1), right after (t2) and 10 minutes following the footbath (t3). The main focus is on the change in subjective perception of warmth distribution between t1 and t3. Moreover, the objective skin temperature distribution and psychosocial scores are assessed. The primary outcome measure is analyzed with a linear mixed effects model (after checking for carry-over effects). Secondary outcome measures are described descriptively.
No animal studies have been conducted to evaluate the effects of ROCTAVIAN on carcinogenesis.

To evaluate vector integration, host genomic DNA was isolated from liver tissues obtained from nonhuman primates at 13 and 26 weeks following intravenous administration of ROCTAVIAN at dose levels of up to 5.4 × 1013 vg/kg. Vector DNA was mostly detected in the form of episomal DNA that was not integrated into the host genome. Vector integration events were observed at low frequencies and distributed throughout the host genome with no indication of clonal enrichment or preference to particular chromosomal locations, including genes associated with oncogenesis in humans [see Warnings and Precautions (5.5) and Clinical Pharmacology (12.2)].

Since ROCTAVIAN vector DNA was detected in testes of adult male mice for at least 6 months following a single intravenous administration at dose level of 2.1 × 1014 vg/kg [see Clinical Pharmacology (12.3)], the potential for vertical transmission to offspring was studied in Rag2-/- immunodeficient mice. A single intravenous administration of ROCTAVIAN at a dose level of 6.7 × 1013 vg/kg into male immunodeficient mice that were mated 37 days later with naïve female mice did not result in adverse effects on fertility rates, pregnancy rates, and litter sizes. Quantitative polymerase chain reaction (qPCR) evaluation of liver tissues from the F1 pups did not detect the vector DNA.
A method for testing chemical and biological substances (pharmaceuticals, foodstuffs, pesticides, solvents, etc.) for harmful effects and for eliminating such effects is claimed. The test method comprises applying the substance to a test animal, allowing the substance to act for a sufficient time, and determining the no. of protrusions with a low cell-organ content (plasma polypi) in the blood plasma of the animal by reverse centrifugation and counting or by comparative counting of the plasma polypi in histological sections from the tissue of the animal. If the test result is positive, the substance is opt. combined with a cpd. (I) which reduced plasma polypus formation. The method is based on the findings that (a) certain substances (e.g. monoiodoacetate and Na acetylsalicylate) increase plasma polypus formation, esp. in pregnant females; (b) there is a correlation between plasma polypus formation and pathogenesis during gestation; and (c) cpds. (I) counteract the pathogenic effects of the substances.
Intraventricular hemorrhage (IVH) is a complication of a spontaneous intracerebral hemorrhage. Standard treatment is with external ventricular drain (EVD). Intraventricular thrombolysis may improve mortality but does not improve functional outcomes. We present our initial experience with a novel irrigating EVD (IRRAflow) that automates continuous irrigation with thrombolysis.Single-center case-control study including patients with IVH treated with EVD compared to IRRAflow. We compared standard demographics, treatment, and outcome parameters between groups. We developed a brain phantom injected with a human clot and assessed clot clearance using EVD/IRRAflow approaches with CT imaging.Twenty-one patients were treated with standard EVD and 9 patients with IRRAflow. Demographics were similar between groups. Thirty-three percent of patients with EVD also had at least one dose of t-PA and 89% of patients with IRRAflow received irrigation with t-PA (p = 0.01). Mean drain days were 8.8 for EVD versus 4.1 for IRRAflow (p = 0.02). Days-to-clearance of ventricular outflow was 5.8 for EVD versus 2.5 for IRRAflow (p = 0.02). Overall clearance was not different. Thirty-seven percent of EVD patients achieved good outcome (mRS ≥ 3) at 90 days versus 86% of IRRAflow patients (p = 0.03). Assessing only t-PA, reduction in mean days-to-clearance (p = 0.0004) and ICU days (p = 0.04) was observed. In the benchtop model, the clot treated with IRRAflow and t-PA showed a significant reduction of volume compared to control.Irrigation with IRRAflow and t-PA is feasible and safe for patients with IVH. Improving clot clearance with IRRAflow may result in improved clinical outcomes and should be incorporated into randomized trials.
Propoxyphene napsylate and acetaminophen tablets are a combination product containing propoxyphene and acetaminophen. Overdose of propoxyphene napsylate and acetaminophen tablets may present with the signs and symptoms of propoxyphene overdose, acetaminophen overdose or both. Fatalities within the first hour of overdosage are not uncommon.

In all cases of suspected overdosage, call your regional Poison Control Center to obtain the most up-to-date information about the treatment of overdose. This recommendation is made because, in general, information regarding the treatment of overdosage may change more rapidly than do package inserts.

Initial consideration should be given to the management of the CNS effects of propoxyphene overdosage. Resuscitative measures should be initiated promptly.
An image transfer object is disclosed that provides the necessary mechanism to conduct a dynamic transfer operation. The image transfer object includes a static reference to dynamic data. The image data is “dynamic”, in that the user may request additional views of the image. An image recipient computer receives the static reference to identify a source image on a server, and generates a first request, based on the static reference, for a view of the source image to the server. In response, the server transmits data to the image recipient computer. The image recipient computer displays the first view of the source image for viewing by the user. The user may then select a different portion of the source image, and/or a different resolution to designate a second view of the source image. The image recipient computer generates a second request to the image server for the second view, and the image server transmits additional data to generate the second view of the source image. Thereafter, the second view of the source image is displayed at the image recipient computer. A sender of the image may transmit a context for the image via e-mail or the recipient computer may download the image from a Web site. Techniques to configure the dynamic transfer object are also disclosed.
BACKGROUND: Surgical site infections are common in spinal surgeries. It is uncertain whether outcomes in spine surgery patients with vs. without surgical site infection are equivalent. Therefore, we assessed the effects of surgical site infection on postoperative patient-reported outcomes.
METHODS: We enrolled patients who underwent elective spine surgery at 12 hospitals between April 2017 and February 2020. We collected data regarding the patients' backgrounds, operative factors, and incidence of surgical site infection. Data for patient-reported outcomes, namely numerical rating scale, Neck Disability Index/Oswestry Disability Index, EuroQol Five-Dimensional questionnaire, and 12-Item Short-Form Health Survey scores, were obtained preoperatively and 1 year postoperatively. We divided the patients into with and without surgical site infection groups. Multivariate logistic regression analyses were performed to identify the risk factors for surgical site infection. Using propensity score matching, we obtained matched surgical site infection-negative and -positive groups. Student's t-test was used for comparisons of continuous variables, and Pearson's chi-square test was used to compare categorical variables between the two matched groups and two unmatched groups.
RESULTS: We enrolled 8861 patients in this study; 74 (0.8 %) developed surgical site infections. Cervical spine surgery and American Society of Anesthesiologists physical status classification ≥3 were identified as risk factors; microendoscopy was identified as a protective factor. Using propensity score matching, we compared surgical site infection-positive and -negative groups (74 in each group). No significant difference was found in postoperative pain or dysesthesia of the lower back, buttock, leg, and plantar area between the groups. When comparing preoperative with postoperative pain and dysesthesia, statistically significant improvement was observed for both variables in both groups (p < 0.01 for all variables). No significant differences were observed in postoperative outcomes between the matched surgical site infection-positive and -negative groups.
CONCLUSIONS: Patients with surgical site infections had comparable postoperative outcomes to those without surgical site infections.
Enrolled subjects must be on a daily dose of between 8 - 24 mg of buprenorphine for at least 30 days. Once enrolled, subjects will receive lofexidine as follows: Days 1 through 3, 0.6 mg 4 times daily (QID; 2.4 mg daily); Days 4 through 6, 0.8 mg QID (3.2 mg daily), and Day 7 0.8 mg at 8 AM. Subjects will take their scheduled lofexidine doses at approximately 8 AM, 1 PM, 6 PM and 11 PM. Subjects will also reduce their current buprenorphine dose by at least 4 mg on Day 1.
The present invention relates to a novel class of N-hydroxy-naphthalene dicarboxamide and N-hydroxy-biphenyl-dicarboxamide derivatives. The N-hydroxy-naphthalene dicarboxamide and N-hydroxy-biphenyl-dicarboxamide compounds can be used to treat cancer. The N-hydroxy-naphthalene dicarboxamide and N-hydroxy-biphenyl-dicarboxamide compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the N-hydroxy-naphthalene dicarboxamide and N-hydroxy-biphenyl-dicarboxamide derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the N-hydroxy-naphthalene dicarboxamide and N-hydroxy-biphenyl-dicarboxamide derivatives in vivo.
26,562. Woloszynski, R. Nov. 19. No Patent granted (Sealing fee not paid). Hair, removing superfluous.-Consists in a mixture of slaked or unslaked lime with a protective agent such as vaseline, glycerine and the like, adapted to prevent exposure of the lime particles to atmospheric carbon dioxide. An intimate mixture is made so that all the particles of lime are coated. Caustic alkali or other suitable lye may be added.
PURPOSE: To obtain a skin preparation for external use containing an extract of a specific crude drug and having excellent beautifying effect and high safety. CONSTITUTION: This skin preparation contains 0.00001-10wt.%, preferably 0.001-5wt.% (as dried solid content) of extracts of one or more kinds of crude drugs selected from Acanthopanacis Cortex, Araliae Cortex, Sophorae Flos, Rosa Laevigata, Sinomeni caulis et Rhizoma, HIKAI [rhizome of Dioscorea septemloba Thunb., Dioscorea tokoro Makino or Dioscorea collettii Hook. f. var. hypoglauca (Palib.) Pei et Ting] and Inulae Flos as active ingredients. The extracts of the crude drugs have suppressing action on melanogenesis and the effect is remarkably excellent in Acanthopanacis Cortex and Inulae Flos. The skin preparation is prepared in skin lotion, milky lotion, cream, pack, dispersion, cleaning agent, make up cosmetic, ointment, cream agent, liquid for external use, etc., by properly blending the extracts of crude drugs with conventional arbitrary ingredients.  The extracts of these crude drugs are obtained by extracting these crude drugs with a proper solvent (e.g., water-ethyl alcohol mixture) at an ambient temperature or under heating.
The study will investigate the effects of drinking proprietary water over a five-day free-living period and then during a heat stress environment compared to distilled water and a carbohydrate-electrolyte drink on markers of hydration, performance, and cognition. This will be a single-blind between-subjects study design. Participants will report to The University of South Carolina for two visits. At the first visit, potential participants will be explained the procedures and risks of the study and then sign an informed consent. Anthropometrics and demographic data will next be collected. Lastly, participants will be familiarized with specific measures and the testing protocol. Participants will take home study products to consume over 5-free living days in which they will need to keep a food and drink log and collect their first urine void of the day to drop off at the laboratory. After the free-living days, participants will return to the laboratory for their heat stress environment test. They will consume a standardized breakfast, complete questionnaires, then perform a 45-minute exercise protocol in the heat chamber. After the first 45-minutes, there will be a break to complete cognitive measures and return to the heat chamber for another 45-minute exercise protocol. Throughout the exercise protocols, participants will be responding to perceptual questions and blood draws. Following, they will rest for 60 minutes, during which they will answer more perceptual questionnaires and blood measures.
There has recently been an increasing interest in the potential of flavonoids, plant derived compounds found in foods such as fruit and vegetables, to improve cognitive function. Research suggests that flavonoids improve memory and learning, possibly as a result of their anti-inflammatory and neuroprotective effects, for example by increasing cerebral blood flow (CBF), protecting vulnerable neurons, or by stimulating neuronal function and growth. The proposed research will involve a parallel design chronic dietary supplementation trial using a flavonoid-supplement and a matched control containing no flavonoids, to investigate long-term changes in cognitive performance. To understand the neural mechanisms behind potential changes in cognitive performance, resting cerebral blood flow (CBF), blood-oxygen level dependent (BOLD) response during two sensitive tests of cognitive performance, and structural brain changes will be measured in a group of healthy elderly adults (N=70, age range 60-75 years) using magnetic resonance imaging (MRI). Additionally, peripheral vascular health will be measured using flow mediated dilatation (FMD), and bioavailability of flavonoid monomers and metabolites will be determined through analysis of plasma and urine samples. Biomarkers in the blood associated with vascular health and neural functioning as well as markers of interest in relation to the possible mechanisms of action of flavonoids will also be measured. All endpoints will be acquired before and after a 24-week chronic supplementation of either a high flavonoid supplementation or a control product, consumed in addition to participants' normal diet. Measures will also be taken following a 12-week post-intervention washout period in order to investigate whether any beneficial effects are sustained following cessation of supplementation.
The invention provides poly(L-glutamate)-grafted cinnamyl alcohol, a preparation method and a drug-loaded nano-material, and belongs to the field of high polymer chemistry. The structural formula of poly(L-glutamate)-grafted cinnamyl alcohol is shown as the formula I. The invention further provides the preparation method of poly(L-glutamate)-grafted cinnamyl alcohol. The method includes the steps that gamma-benzyl-L-glutamate and triphosgene react, and gamma-benzyl-L-glutamate NCA is obtained; then, triethylamine serves as an initiator to initiate ring opening polymerization of BLG-NCA, benzyl is removed, and PLGA is obtained; cinnamyl alcohol is grafted to PLGA, and PLGA-g-CA is obtained. The invention further provides the drug-loaded nano-material. The microgel synthesized through photocrosslinking has higher stability and will not break and release drugs after entering the organism, more drugs can accumulate in a target area, and a better treatment effect can be achieved.
Patients receive oral relugolix daily plus oral abiraterone acetate (AA) with prednisone daily for up to 24 months in the absence of disease progression or unacceptable toxicity. Patients also undergo standard of care radiation therapy.
30 healthy adults and 30 patients is going to undergo lumbar fusion surgery will be recruited in this study. The assessment will be held before surgery, two months, three months and six months after surgery. Visual pain scale and passive range of motion over lumbar, hip, knee, ankle joint of each subjects will be recorded. Then the maximum voluntary contraction at lower extremity will be measured by electromyography. Finally, the subjects will be asked to do forward reach by dominant upper limb/bilateral upper limbs/arm crossed in the front of chest for three times in standing and sitting position after five practices. The motion data will be collected by 3-dimension video and the muscle activity by electromyography.
South Korea has the highest incidence of gastric cancer worldwide and Helicobacter pylori infection is still prevalent. Clarithromycin-containing triple therapy is still the primary therapy approved by the Korean government. However, studies of antibiotic resistance has shown that regional resistance pattern to antibiotics such as clarithromycin, metronidazole, or quinolone. Recent study in Korea has shown that modified-quadruple therapy has comparable eradication rate to concomitant therapy. However, this study did not explore the antibiotic resistance profile of Helicobacter pylori. And, there has been no comparable study of modified-quadruple therapy with bismuth-containing quadruple therapy. The aim of this study is to compare the eradication rate of modified-quadruple therapy and bismuth-containing quadruple therapy with presenting phenotypic and genotypic antibiotic resistance profile.
<P>PROBLEM TO BE SOLVED: To provide a self-adhesive composition, and a percutaneous absorption-type preparation containing a rubber-based self-adhesive, having an excellent control ability of bleeding, and controlling an increase in crystal deposition of a medicament with time.  <P>SOLUTION: The self-adhesive composition used for the percutaneous absorption-type preparation includes: the medicament; a medicament solubilizer for improving the solubility of the medicament; the rubber-based self-adhesive; polyvinylpyrrolidone; and a higher fatty acid. The polyvinylpyrrolidone is contained in an amount effective for inhibiting volatilization of the medicament solubilizer. The higher fatty acid preferably contains isostearic acid. The medicament solubilizer preferably contains N-methyl-2-pyrrolidone.  <P>COPYRIGHT: (C)2010,JPO&INPIT